JP2012508025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508025A5 JP2012508025A5 JP2011535731A JP2011535731A JP2012508025A5 JP 2012508025 A5 JP2012508025 A5 JP 2012508025A5 JP 2011535731 A JP2011535731 A JP 2011535731A JP 2011535731 A JP2011535731 A JP 2011535731A JP 2012508025 A5 JP2012508025 A5 JP 2012508025A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- grp78
- cancer
- antibody
- cripto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 claims description 40
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 claims description 40
- 101150112743 HSPA5 gene Proteins 0.000 claims description 40
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 claims description 40
- 101150028578 grp78 gene Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 238000011275 oncology therapy Methods 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000009918 complex formation Effects 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 230000003463 hyperproliferative effect Effects 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 244000089409 Erythrina poeppigiana Species 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 235000009776 Rathbunia alamosensis Nutrition 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000004404 adrenal cortex Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000002287 radioligand Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 101150054147 sina gene Proteins 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000002456 taxol group Chemical group 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11257908P | 2008-11-07 | 2008-11-07 | |
| US61/112,579 | 2008-11-07 | ||
| PCT/US2009/063748 WO2010054328A2 (en) | 2008-11-07 | 2009-11-09 | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090036A Division JP2015133984A (ja) | 2008-11-07 | 2015-04-27 | Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508025A JP2012508025A (ja) | 2012-04-05 |
| JP2012508025A5 true JP2012508025A5 (enExample) | 2012-12-06 |
| JP5805538B2 JP5805538B2 (ja) | 2015-11-04 |
Family
ID=42153627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535731A Expired - Fee Related JP5805538B2 (ja) | 2008-11-07 | 2009-11-09 | Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法 |
| JP2015090036A Withdrawn JP2015133984A (ja) | 2008-11-07 | 2015-04-27 | Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090036A Withdrawn JP2015133984A (ja) | 2008-11-07 | 2015-04-27 | Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100135904A1 (enExample) |
| EP (1) | EP2350131B1 (enExample) |
| JP (2) | JP5805538B2 (enExample) |
| CN (1) | CN102272157B (enExample) |
| AU (1) | AU2009313255B2 (enExample) |
| CA (1) | CA2743057C (enExample) |
| WO (1) | WO2010054328A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102692505A (zh) * | 2011-03-21 | 2012-09-26 | 中国医学科学院肿瘤研究所 | 一种改进的免疫共沉淀技术方法 |
| EP2970443A4 (en) | 2013-03-14 | 2017-01-11 | Parkash S. Gill | Cancer treatment using antibodies that bind cell surface grp78 |
| US10117908B2 (en) | 2013-10-17 | 2018-11-06 | Grant Labs, Inc. | Suppression of cellular transformation and dysplasia by topical application of lefty |
| EP4614154A3 (en) | 2017-10-13 | 2025-11-26 | Nibec Co., Ltd. | Grp78-derived peptide for identifying high-efficiency stem cells |
| US20210009946A1 (en) * | 2017-10-13 | 2021-01-14 | Nibec Co., Ltd. | Method for selecting highly efficient stem cell, using protein marker grp78 |
| US12060410B2 (en) * | 2020-04-20 | 2024-08-13 | Creative Bio Therapeutics LLC | Antivirus proteins having a Kringle 5 subunit |
| CN116041477B (zh) * | 2022-10-13 | 2023-08-08 | 呈诺再生医学科技(北京)有限公司 | Tdgf1基因在制备治疗衰老相关疾病或逆转细胞衰老的药物中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5206347A (en) | 1985-08-06 | 1993-04-27 | La Jolla Cancer Research Foundation | Isolation and use of receptors binding to a peptide column |
| US4682195A (en) | 1985-09-30 | 1987-07-21 | General Electric Company | Insulated gate device with configured emitter contact pad |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4959463A (en) | 1985-10-15 | 1990-09-25 | Genentech, Inc. | Intermediates |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
| US4816571A (en) | 1987-06-04 | 1989-03-28 | Applied Biosystems, Inc. | Chemical capping by phosphitylation during oligonucleotide synthesis |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5602244A (en) | 1988-05-26 | 1997-02-11 | Competitive Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
| US5045451A (en) | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
| US5141813A (en) | 1989-08-28 | 1992-08-25 | Clontech Laboratories, Inc. | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis |
| US5767072A (en) | 1989-09-14 | 1998-06-16 | Board Of Regents, The University Of Texas System | Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5766855A (en) | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| DE4204650C1 (enExample) | 1992-02-15 | 1993-07-08 | Hoffmeister, Helmut, Dr., 4400 Muenster, De | |
| US5428148A (en) | 1992-04-24 | 1995-06-27 | Beckman Instruments, Inc. | N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis |
| GB9211979D0 (en) | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5438131A (en) | 1992-09-16 | 1995-08-01 | Bergstrom; Donald E. | 3-nitropyrrole nucleoside |
| US5578706A (en) | 1993-11-04 | 1996-11-26 | Board Of Regents, The University Of Texas | Methods and compositions concerning homogenous immunotoxin preparations |
| US5574146A (en) | 1994-08-30 | 1996-11-12 | Beckman Instruments, Inc. | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators |
| US5554744A (en) | 1994-09-23 | 1996-09-10 | Hybridon, Inc. | Method for loading solid supports for nucleic acid synthesis |
| US5705629A (en) | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| DE19638745C2 (de) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| US5908845A (en) | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| ES2374534T3 (es) | 1998-03-20 | 2012-02-17 | Commonwealth Scientific And Industrial Research Organisation | Control de la expresión de genes. |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US7078176B2 (en) * | 2001-01-26 | 2006-07-18 | The United States Of America As Represented By The Department Of Health And Human Serivices | Detection and quantification of Cripto-1 |
| AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| RS20110024A (sr) * | 2001-04-26 | 2011-08-31 | Biogen Idec Ma Inc. | Antitela koja blokiraju cripto i njihova upotreba |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| AU2004274433B2 (en) * | 2003-09-15 | 2010-08-12 | Research Development Foundation | Cripto antagonism of activin and TGF-beta signaling |
| US20050191294A1 (en) * | 2003-12-31 | 2005-09-01 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
| CN1281279C (zh) * | 2004-09-16 | 2006-10-25 | 浙江大学 | 针对表皮生长因子基因的小干扰核糖核酸分子及其用途 |
| CN1923276A (zh) * | 2005-09-02 | 2007-03-07 | 上海睿星基因技术有限公司 | NFκB信号通路的重要调控蛋白PAK7 |
| JP5374360B2 (ja) * | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物 |
| US11516124B2 (en) | 2021-03-26 | 2022-11-29 | Cisco Technology, Inc. | Leveraging multicast listener discovery for discovering hosts |
-
2009
- 2009-11-09 EP EP09825562.3A patent/EP2350131B1/en not_active Not-in-force
- 2009-11-09 CN CN200980154121.9A patent/CN102272157B/zh not_active Expired - Fee Related
- 2009-11-09 CA CA2743057A patent/CA2743057C/en not_active Expired - Fee Related
- 2009-11-09 AU AU2009313255A patent/AU2009313255B2/en not_active Ceased
- 2009-11-09 JP JP2011535731A patent/JP5805538B2/ja not_active Expired - Fee Related
- 2009-11-09 US US12/615,033 patent/US20100135904A1/en not_active Abandoned
- 2009-11-09 WO PCT/US2009/063748 patent/WO2010054328A2/en not_active Ceased
-
2015
- 2015-04-27 JP JP2015090036A patent/JP2015133984A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508025A5 (enExample) | ||
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| RU2013155455A (ru) | Антитела для лечения раковых заболеваний, при которых эскспрессируется клаудин 6 | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| Sharma et al. | ErbBs in lung cancer | |
| RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| JP2008531576A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2011126896A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| JP2011103891A5 (enExample) | ||
| JP2005504044A5 (enExample) | ||
| US9833431B2 (en) | Pharmaceutical combinations for the treatment of cancer | |
| RU2015105786A (ru) | Комбинированная терапия ингибиторами igf1r и pi3k | |
| JP2009506054A5 (enExample) | ||
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| JPWO2022270524A5 (enExample) | ||
| Zhang et al. | 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer | |
| NZ703786A (en) | Fgfr1 extracellular domain combination therapies | |
| Wang et al. | Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL3 | |
| JP2022009980A (ja) | 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット | |
| Yao et al. | Direct cellular targets and anticancer mechanisms of the natural product oridonin |